BRIEF — Boehringer bolsters CNS research with Domain deal

Domain Therapeutics has announced a multi-target drug discovery collaboration and licensing agreement with family-owned German pharma major Boehringer Ingelheim on orphan G protein-coupled receptors (GPCRs) in the central nervous system (CNS) disease area.

The collaboration combines the expertise of Domain Therapeutics, a French and Canadian biopharmaceutical company, in the discovery of GPCR targeting drugs in CNS, oncology and immuno-oncology, with Boehringer’s expertise in the discovery and clinical development of therapeutics on multiple indications.

Privately-held Domain will be eligible for an upfront payment, discovery, development and commercial milestone payments as well as royalties on sales. Financial details were not disclosed.